Treatment as prevention: Will it work?

Eurosurveillance

Volumn 16, Issue 48, 2011, Pages

  van de Laar, M J ^a   Pharris, A ^a  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE SURVEILLANCE; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PROPHYLAXIS; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 83255189457     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Editorial

References (29)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
2. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, Chillag K, et al., for the TDF2 Study Group. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2011 July 17-20; Rome, Italy.
3. University of Washington International Clinical Research Center. Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. Partners PrEP Study. [Press Release]. Available from: http://depts.washington.edu/astda/resources/PrEP_PressRelease-UW_13Jul2011.pdf Full study
4. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One. 2011; 6(10):e25828.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
7. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378(9787):269-78.
8. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57.
9. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.
10. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.
11. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
12. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397-404.
13. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe: 2010. Stockholm, 2011. Available from: http://ecdc.europa.eu/en/publications/Publications/101129_SUR_HIV_2009.pdf
14. Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Antoniadou A, Lazanas M, et al. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill. 2011;16(36). Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19962
15. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2011: The state of the drugs problem in Europe. Lisbon: EMCDDA 2011. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf
16. Wiessing L, Likatavicius G, Hedrich D, Guarita B, Van de Laar M, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill. 2011;16(48). pii=20031. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20031
17. Likatavicius G, van de Laar MJ. HIV infection and AIDS in the European Union and European Economic Area, 2010. Euro Surveill. 2011;16(48). pii=20030. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20030
18. European Centre for Disease Prevention and Control. Technical Report: Increasing the uptake and effectiveness in the European Union: Evidence synthesis for Guidance on HIV testing. Stockholm: ECDC; 2010. Available from: http://ecdc.europa.eu/en/publications/Publications/101129_TER_HIV_testing_evidence.pdf
19. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793-800.
20. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778-89.
21. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372(9639):669-84.
22. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet. 2008;372(9641):845-59.
23. European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. Evidence for the effectiveness of interventions to prevent infections among people who inject drugs. Part 1: Needle and syringe programmes and other interventions for preventing hepatitis C, HIV and injecting risk behaviour. Stockholm: ECDC; 2011. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_145115_EN_ECDC-EMCDDA%20Part%201%20web.pdf
24. European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. Evidence for the effectiveness of interventions to prevent infections among people who inject drug, Part 2: Drug treatment for preventing hepatitis C, HIV and injecting risk behaviour among people who inject drugs. Stockholm: ECDC; 2011. Available from: http://ecdc.europa.eu/en/publications/Publications/111129_TER_ECDC-EMCDDA_part2.pdf
25. European Centre for Disease Prevention and Control. Technical Report. Effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe. Stockholm: ECDC, 2009. Available from: http://ecdc.europa.eu/en/publications/Publications/0911_TER_Lit_Review_Effect_HIVSTI_prev_interv_for_MSM.pdf
26. Kelley CF, Haaland RE, Patel P, Evans-Strickfaden T, Farshy C, Hanson D, et al. HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. J Infect Dis. 2011;204(5):761-7.
27. European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. Prevention and control of infectious disease among people who inject drugs. Stockholm: ECDC, 2011. Available from: http://www.ecdc.europa.eu/en/publications/Publications/111012_Guidance_ECDC-EMCDDA.pdf
28. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011;16(48). pii=20032. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20032
29. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2011- 2015 strategy: Getting to zero. UNAIDS, Geneva: UNAIDS, 2010. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/JC2034_UNAIDS_Strategy_en.pdf